Five-year clinical outcomes for neoadjuvant nivolumab in resectable NSCLC compare favorably with historical outcomes. MPR and PD-L1 positivity trended toward improved RFS, though definitive conclusions are limited by cohort size.
No takes yet. Share an insight, caveat, or question.
Rosner et al. (2023) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: